Update on peripartum cardiomyopathy

Obstetrics and Gynecology Clinics of North America

Volumn 37, Issue 2, 2010, Pages 283-303

  Cruz, Meredith O ^a   Briller, Joan ^a   Hibbard, Judith U ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cardiac disease; Congestive heart failure; Peripartum cardiomyopathy; Pregnancy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CAPTOPRIL; CARDIAC MYOSIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; GAMMA INTERFERON; HYDRALAZINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; INTERLEUKIN 1; INTERLEUKIN 6; ISOXSUPRINE; LISINOPRIL; MAGNESIUM SULFATE; METOPROLOL; PROLACTIN; RITODRINE; SALBUTAMOL; TERBUTALINE; THIAZIDE DIURETIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; UTERUS SPASMOLYTIC AGENT; VALSARTAN;

ADRENERGIC ACTIVITY; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CLINICAL ASSESSMENT; CONGESTIVE CARDIOMYOPATHY; CYTOKINE RESPONSE; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; ETHNICITY; HEART AFTERLOAD; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEMODYNAMIC STRESS; HEREDITY; HORMONAL REGULATION; HUMAN; HUMORAL IMMUNITY; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; IMMUNE RESPONSE; LUNG EDEMA; MALNUTRITION; MATERNAL AGE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPARTUM CARDIOMYOPATHY; PREGNANCY; PREGNANCY DISORDER; PRIORITY JOURNAL; PROGNOSIS; PROLACTIN RELEASE; PROTEIN EXPRESSION; RISK FACTOR; SIDE EFFECT; SOCIAL STATUS; TACHYCARDIA; TOCOLYSIS; VIRUS MYOCARDITIS; WATER RETENTION; ANIMAL; AUTOIMMUNE DISEASE; BIOSYNTHESIS; FEMALE; GENETIC PREDISPOSITION; HEART MUSCLE CELL; HEMODYNAMICS; INFLAMMATION; MYOCARDITIS; PHYSIOLOGY; PREGNANCY COMPLICATION; PRENATAL CARE; REVIEW; VIROLOGY; VIRUS INFECTION;

ANIMALS; APOPTOSIS; AUTOIMMUNE DISEASES; CARDIOMYOPATHIES; CYTOKINES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMODYNAMICS; HUMANS; INFLAMMATION; MYOCARDITIS; MYOCYTES, CARDIAC; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PRENATAL CARE; PROGNOSIS; PROLACTIN; RISK FACTORS; VIRUS DISEASES;

EID: 79952015701     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2010.02.003     Document Type: Article

References (103)

1. Gouley BA, McMillan TM, Bellet S. Idiopathic myocardial degeneration associated with pregnancy and especially the puerperium. Am J Med Sci 1937;19: 185-99.
2. Mayosi B. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart 2007;93:1176-83.
3. Whitehead SJ, Berg CJ, Chang J. Pregnancy related mortality due to cardiomyopathy: United States, 1991-1997. Obstet Gynecol 2003;102(6):1326-31.
4. Kuklina VE, Callaghan WM. Cardiomyopathy and other myocardial disorders among hospitalizatons for pregnancy in the United States 2004-2006. Obstet Gynecol 2010;115:93-100.
5. Hilfiker-Kleiner D, Sliwa K, Drexler H. Peripartum cardiomyopathy: recent insights into its pathophysiology. Trends Cardiovasc Med 2008;18:173-9.
6. Ribner SH, Silverman RI. Peripartal cardiomyopathy. In: Elkayam U, Gleicher N, editors. Cardiac problems in pregnancy: diagnosis and management of maternal and fetal disease. 2nd edition. New York: Alan R Liss; 1990. p. 115-27.
7. Cunningham FG, Pritchard JA, Hankins GD, et al. Peripartum heart failure: idiopathic cardiomyopathy or compounding cardiovascular events? Obstet Gynecol 1986;67:157-68.
8. Robson SC, Hunter S, Boys RJ, et al. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 1989;256:1060-5.
9. Fett JD, Christie LG, Carraway RD, et al. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 2005;80:1602-6.
10. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000;283:1183-8.
11. Ntusi NB, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy: a systematic review [review]. Int J Cardiol 2009;131(2):168-79.
12. Krause PJ, Ingardia CJ, Pontius LT, et al. Host defense during pregnancy: neutrophil chemotaxis and adherence. Am J Obstet Gynecol 1987;157:274-80.
13. Farber PA, Glasgow LA. Viral myocarditis during pregnancy: encephalomyocarditis virus infection in mice. Am Heart J 1970;80:96-102.
14. Lyden DC, Huber SA. Aggravation of Coxsackie virus, group B, type-3-induced myocarditis and increase in cellular immunity to myocyte antigens in pregnant Balb/c mice and animal treated with progesterone. Cell Immunol 1984;87:462-72.
15. Rizeq MN, Rickenbacher PR, Fowler MB, et al. Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol 1994;74:474-7.
16. O'Connell JB, Costanzo-Nordin MR, Subramanian R, et al. Peripartum cardiomyopathy: clinical, hemodynamic, histologic, and prognostic characteristics. J Am Coll Cardiol 1986;8:52-6.
17. Sanderson JE, Olsen EG, Gatei D. Peripartum heart disease: an endomyocardial biopsy study. Br Heart J 1986;56:285-91.
18. Midei MG, DeMent SH, Feldman AM, et al. Peripartum myocarditis and cardiomyopathy. Circulation 1990;81:922-8.
19. Melvin KR, Richardson PJ, Olsen EG, et al. Peripartum cardiomyopathy due to myocarditis. N Engl J Med 1982;307:731-4.
20. Felker GM, Jaeger CJ, Klodas E, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J 2000;140:785-91.
21. Bultmann BD, Klingel K, Nabauer M, et al. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol 2005; 193:363-5.
22. Ansari AA, Neckelmann N, Wang YC, et al. Immunologic dialogue between cardiac myocytes, endothelial cells and mononuclear cells. Clin Immunol Immunopathol 1993;68:208-14.
23. Sliwa K, Skudicky D, Bergemann A, et al. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/ APO-1. J Am Coll Cardiol 2000;35:701-5.
24. Sliwa K, Forster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2005;27:441-6.
25. Ansari AA, Fett JD, Carraway RE, et al. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol 2002;23: 301-24.
26. Sundstrom JB, Fett JD, Carraway RD, et al. Is peripartum cardiomyopathy an organ-specific autoimmune disease? Autoimmun Rev 2002;1:73-7.
27. Warraich RS, Sliwa K, Damasceno A, et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Am Heart J 2005;150:263-9.
28. Warraich RS, Young JB, Sestier F, et al. Clinical and prognostic relevance of Ig-G3 reactivity in heart failure: a substudy of vasogen's immune modulation therapy in patients with chronic heart failure. J Am Coll Cardiol 2004;43:226A.
29. Drexler H. Changes in the peripheral circulation in heart failure. Curr Opin Cardiol 1995;10:268-73.
30. Mann DL. Stress activated cytokines and the heart: from adaptation to maladaptation. Cytokine Growth Factor Rev 1996;7:341-54.
31. Satoh M, Nakamura M, Akatsu T, et al. C-reactive protein coexpresses with tumour necrosis factor-alpha in the myocardium in human dilated cardiomyopathy. Eur Heart J 2005;7:748-54.
32. Poppas A, Shroff SG, Korcarz CE, et al. Serial assessment of the cardiovascular system in normal pregnancy. Role of arterial compliance and pulsatile arterial load. Circulation 1997;95(10):2407-15.
33. Geva T, Mauer MB, Striker L, et al. Effects of physiologic load of pregnancy on left ventricular contractility and remodeling. Am Heart J 1997;133:53-9.
34. Lampert MB, Weinert L, Hibbard J, et al. Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol 1997;176:189-95.
35. Wencker D, Chandra M, Nguyen K, et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003;111:1497-504.
36. Narula J, Kolodgie FD, Virmani R. Apoptosis and cardiomyopathy. Curr Opin Cardiol 2000;15:183-8.
37. MacLellan WR, Schneider MD. Death by design: programmed cell death in cardiovascular biology and disease. Circ Res 1997;81:137-44.
38. Yussman MG, Toyokawa T, Odley A, et al. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med 2002;8:725-30.
39. Adams JW, Sakata Y, Davis MG, et al. Enhanced G alpha q signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A 1998;95:10140-5.
40. Hayakawa Y, Chandra M, Miao W, et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of G{alpha}q transgenic mice. Circulation 2003;108:3036-41.
41. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128:589-600.
42. Leinwand LA. Molecular events underlying pregnancy-induced cardiomyopathy. Cell 2007;128:437-8.
43. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 2002;173:219-38.
44. Bryant EE, Douglas BH, Ashburn AD. Circulatory changes following prolactin administration. Am J Obstet Gynecol 1973;115:53-7.
45. Negoro S, Kunisada K, Fujio Y, et al. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenationinduced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 2001;104:979-81.
46. Hilfiker-Kleiner D, Meyer GP, Schieffer E, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 2007;50:2354-5.
47. Cenac A, Simonoff M, Moretto P, et al. A low plasma selenium is a risk factor for peripartum cardiomyopathy: a comparative study in Sahelian Africa. Int J Cardiol 1992;36:57-9.
48. Fillmore SJ, Parry EO. The evolution of peripartal heart failure in Zaria, Nigeria. Some etiologic factors. Circulation 1977;56:1058-61.
49. Pierce JA, Price BO, Joyce JW. Familial occurrence of postpartal heart failure. Arch Intern Med 1963;111:151-5.
50. Massad LS, Reiss CK, Mutch DG, et al. Familial peripartum cardiomyopathy after molar pregnancy. Obstet Gynecol 1993;81:886-8.
51. Pearl W. Familial occurrence of peripartum cardiomyopathy. Am Heart J 1995; 129:421-2.
52. Voss EG, Reddy CV, Detrano R, et al. Familial dilated cardiomyopathy. Am J Cardiol 1984;54:456-7.
53. Fett JD, Sundstrom BJ, Etta King M, et al. Mother-daughter peripartum cardiomyopathy. Int J Cardiol 2002;86:331-2.
54. Kuhl U, Pauschinger M, Michel Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005;111:887-93.
55. HorwitzMS, Knudsen M, Fine C, et al. Transforming growth factor-beta inhibits Coxsackievirus-mediated autoimmune myocarditis. Viral Immunol 2006;19:722-33.
56. Lang C, Sauter M, Szalay G, et al. Connective tissue growth factor: a crucial cytokine-mediating cardiac fibrosis in ongoing enterovirus myocarditis. J Mol Med 2007;86:49-60.
57. Gluck B, Schmidtke M, Merkle I, et al. Persistent expression of cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice. J Mol Cell Cardiol 2001;33:1615-26.
58. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 2006;368:687-93.
59. Sliwa K, Forster O, Zhanje F, et al. Outcome of subsequent pregnancy in patients with documented peripartum cardiomyopathy. Am J Cardiol 2004;93: 1441-3, A10.
60. Coulson C, Thorp JM Jr, Mayer D, et al. Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model. Obstet Gynecol 1996;87:610-2.
61. Wittstein IS, Thiemann DR, Lima JAC, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005;352:539-48.
62. Jahns R, Boivin V, Hein L, et al. Direct evidence for a b1-adrenergic receptordirected autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004;113:1419-29.
63. Freedman NJ, Lefkowitz RJ. Anti-b1-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest 2004;113:1379-82.
64. Lampert MB, Lang RM. Peripartum cardiomyopathy. Am Heart J 1995;130: 860-70.
65. Homans DC. Peripartum cardiomyopathy. N Engl J Med 1985;312:1432-7.
66. Koide T, Saito Y, Sakemoto T, et al. Peripartal cardiomyopathy in Japan: a critical reappraisal of the concept. Jpn Heart J 1972;13:488-501.
67. Lampert MB, Hibbard J, Weinert L, et al. Peripartum heart failure associated with prolonged tocolytic therapy. Am J Obstet Gynecol 1993;168:493-5.
68. Hibbard JU. Case-control study of long-term terbutaline therapy and peripartum cardiomyopathy. Hypertens Pregnancy 1996;15:183-91.
69. Pisani RJ, Rosenow EC. Pulmonary oedema associated with tocolytic therapy. Ann Intern Med 1989;110:714-8.
70. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation 1971;44: 964-8.
71. Elkayam U, Akhter MW, Singh HS, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 2005;111:2050-5.
72. Elkayam U, Akhter MW, Singh HS, et al. Peripartum cardiomyopathies: a review. Am J Obstet Gynecol 1984;148:805-18.
73. Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 2007;100:302-4.
74. Hameed AB, Chan K, Ghamsary M, et al. Longitudinal changes in the B-type natriuretic peptide levels in normal pregnancy and post partum. Clin Cardiol 2009;32:E60-2.
75. Garrison E, Hibbard JU, Studee L, et al. Brain natriuretic peptide as a marker for heart disease in pregnancy. Am J Obstet Gynecol 2005;193:S83.
76. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
77. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B type natriuretic peptide in the evaluation andmanagement of acute dyspnea.NEngl JMed2004;350:647-54.
78. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 2009;119:e391-479.
79. Di Bella G, de Gregorio C, Minutoli F, et al. Early diagnosis of focal myocarditis by cardiac magnetic resonance. Int J Cardiol 2007;117:280-1.
80. Mahrholdt H, Goedecke C, Wagner A, et al. Multimedia article. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004;109:1250-8.
81. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 2007;28:3076-93.
82. Abboud J, Murad Y, Chen-Scarabelli C, et al. Peripartum cardiomyopathy: a comprehensive review [review]. Int J Cardiol 2007;118:295-303.
83. Chapa JB, Heiberger B, Weinert L, et al. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol 2005;105:1303-8.
84. Hibbard J, Lindheimer M, Lang R. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol 1999; 94(2):311-6.
85. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57.
86. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG Trial. Eur Heart J 2006;27:178-86.
87. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-8.
88. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87:VI94-101.
89. Dries DL, Rosenberg YD, Waclawiw MA, et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm. Evidence for gender differences in the studies of LV dysfunction trials. J Am Coll Cardiol 1997;29:1074-80.
90. Freudenberger RS, Hellcamp AS, Halperin JL. Risk of thromboembolism in heart failure: analysis of the sudden cardiac death in heart failure trial (SCD-HEFT). Circulation 2007;115:2637-41.
91. Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 2009;15:645-50.
92. Cibils LA, Pose SV, Zuspan FP. Effect of l-norepinephrine infusion on uterine contractility and cardiovascular system. Am J Obstet Gynecol 1962;84:307.
93. Habedank D, Kuhnle Y, Elgeti T, et al. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur J Heart Fail 2008;10:1149-51.
94. Hopp L, Weisse AB, Iffy L. Acute myocardial infarction in a healthy mother using bromocriptine for mild suppression. Can J Cardiol 1996;12:415-8.
95. Sliwa K, Skudicky D, Candy G, et al. The addition of pentoxyfylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 2002;4:305-9.
96. Bozkurt B, Villaneuva FS, Holubkov R, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 1999;34:177-80.
97. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103:2254-9.
98. Zimmermann O, Kochs M, Zwaka TP, et al. Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy. Int J Cardiol 2005; 104:92-100.
99. Fett JD. Monitoring subsequent pregnancy in recovered peripartum cardiomyopathy mothers. Criti Pathw Cardiol 2009;8:172-4.
100. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 2007;50:e159-241.
101. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006;152:509-13.
102. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001;344:1567-71.
103. Fett JD, Fristoe KL, Welsh SN. Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers. Int J Gynaecol Obstet 2010; 109(1):34-6.